Skip to Content

Merrimack is a biopharmaceutical company based in Cambridge, Massachusetts that is outthinking cancer to ensure that patients and their families live fulfilling lives. Its mission is to transform cancer care through the smart design and development of targeted solutions based on a deep understanding of cancer pathways and biological markers. All of Merrimack's development programs fit into its strategy of 1) understanding the biological problems it is trying to solve, 2) designing specific solutions and 3) developing those solutions for biomarker-selected patients. This three-pronged strategy seeks to optimize patient outcomes.

Investors

Press Releases

March 27, 2024

Summary Toggle Merrimack Receives $225 Million Milestone Payment from Ipsen

Special Meeting of Stockholders to Approve Plan of Dissolution Scheduled for Friday, May 10, 2024 at 10:00 a.m. Eastern Standard Time CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 27, 2024-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced that it has

PDF Version
March 7, 2024

Summary Toggle Merrimack Reports Full Year 2023 Financial Results

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 7, 2024-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its full year 2023 financial results for the period ended December 31, 2023 . “As Ipsen reported in February, the U.S.

PDF Version
February 13, 2024

Summary Toggle Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

FDA Approval Triggers $225 Million Milestone Payment from Ipsen to Merrimack Merrimack Expects to Hold Special Meeting of Stockholders to Approve Plan of Dissolution in May 2024 Following Approval of Plan of Dissolution, Merrimack Expects to Issue a Liquidating Dividend Currently Estimated to be

PDF Version

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Back to top

Merrimack Pharmaceuticals, Inc.
One Broadway, 14th floor
Cambridge, MA 02142
617-720-8606
info@merrimack.com

© 2024 Merrimack Pharmaceuticals.